2 Information about enzalutamide

Marketing authorisation indication

2.1 Enzalutamide (Xtandi, Astellas) is indicated for 'the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price of a 112‑capsule pack of 40 mg enzalutamide is £2,734.67 (excluding VAT; BNF online, accessed May 2020). The daily dose of enzalutamide is 160 mg and costs £97.67.

2.4 The company has a commercial arrangement. This makes enzalutamide available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)